SOST and osteoporosis: In addition, insights into a potential inhibitory role of sclerostin in cardiovascular calcification are essential in light of the current development of anti-sclerostin treatment for osteoporosis patients, which conceivably could contribute to increased vascular calcification and cardiovascular risk [81,84].